- About Mesothelioma
- Mesothelioma Cause
- Mesothelioma Symptoms
- Mesothelioma Diagnosis
- Mesothelioma Stages
MESOTHELIOMA CLINICAL TRIALS
NEW! The Mesothelioma Center at the New York-Presbyterian Hospital and Columbia University is recruiting patients for a new clinical trial on treatment of mesothelioma with targeted radiation an chemotherapy. This multimodality treatment is an innovative approach led by oncologist Dr. Robert Taub. Click here to learn more.
CLINICAL TRIAL BASICS
Clinical trials are studies of the safety and/or effectiveness of new drugs being tested on humans. For mesothelioma, trials are being conducted to find a better and more effective means of treatment. Anyone interested in participating in a clinical trial should discuss the particular trial thoroughly with their doctor before a making a decision on whether it is right for them.
All clinical trials carry potential benefits and risks, and it is important that you have a complete understanding of what you might expect. For instance, since clinical trials are often conducted at larger cancer centers, in many cases, travel may be necessary to receive treatment and routine tests. On the other hand, care is provided at top-notch facilities by physicians who are leaders in the field of cancer research. Another benefit would be having access to the new drug before it is widely available, however, the new drug may ultimately be proven not as effective as the “standard” of care.
Eligibility requirements for clinical trials are not the same; each study has specific guidelines to participate. Some trials allow participation after other treatments have failed, while others require that the patient have no prior treatment. Your doctor should be able to advise you which trial might be the best fit in your particular case.
Some treatment trials are “randomized”, meaning the new treatment is compared with a current standard of treatment. Depending on which arm of the protocol you are assigned, you may receive the new treatment or the standard. You should be informed in advance of this eventuality by the doctor conducting the trial. Placebos (pills that contain no active ingredient) are rarely used in cancer trials.
For more information on the terminology associated with clinical trials, visit our clinical trial glossary.
TRIAL PHASES
Though mesothelioma has no cure, there are clinical trials currently underway to test new drugs and procedures in the fight against the disease. All clinical trials or studies are divided into different phases:
Phase I trials usually enroll only a small number of people and test how new drugs or procedures should be administered. Click here for an in-depth description of Phase I trials.
Phase II trials give early information about whether or not a new drug or procedure works and also provide information about safety and benefit. Click here for an in-depth description of Phase II trials.
Phase III trials compare promising new drugs or procedures with the current standard treatment. Large numbers of people from across the nation usually participate in Phase III trials and receive either the new treatment or the standard treatment. Click here for an in-depth description of Phase III trials.
An explanation of the Clincial Trials process
Common questions and answers about Clincial Trials
ELIGIBILITY
In order to be sure the study results are accurate, trial participants in all phases must fit a certain profile. Eligibility for mesothelioma trials are often specific as to age, how long it has been since therapy, stage of disease, and other characteristics. To find out about the eligibility requirements and other information for the trials listed below, click on the clinical trial web site listed after each trial or call one of our MW Coordinators toll-free at 1-877-367-6376.
CLINICAL TRIALS AND MEDICARE
If you choose to enter a clinical trial and are on Medicare, it is important that you have a complete understanding of the trial itself, and what costs will or will not be covered under your Medicare policy.
Clinical trials for cancer are currently covered if:
- The trial is funded by the National Cancer Institute (NCI), the NCI-Designated Cancer Centers, the NCI-Sponsored Clinical Trials Cooperative Groups or other Federal agencies that fund cancer research.
- The goal of the trial is to diagnose or treat cancer (cancer prevention trials are not covered).
More on clinical trials and medicare.
CURRENT CLINICAL TRIALS
The National Cancer Institute states that the purpose of most listed clinical trials is to test new cancer treatments or new methods of diagnosing, screening for or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in each clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.
At present, the following trials are actively testing new drugs or treatments for mesothelioma. They are listed by title with a short description and have no particular order or endorsement.
- Phase III Study of Suberoylanilide Hydroxamic Acid (SAHA) Versus Placebo in Advanced Malignant Pleural Mesothelioma
Click here for an abstract of this trial - NEW! Phase II Study of Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma
Click here for an abstract of this trial
- Phase II Study Using Chemotherapy Followed by Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced But Unresectable Malignant Pleural Mesothelioma
Click here for an abstract of this trial
- A Randomized Phase II Study of a Lung-Sparing Combined Modality Protocol for the Treatment of Malignant Pleural Mesothelioma: The Columbia Protocol
Click here for an abstract of this trial: For health professionals | For patientsClick here for the complete protocol from Columbia University Medical Center (PDF file)
Click here to read the consent form for this trial (PDF file)
Contact our MW Coordinators toll-free at 1-877-367-6376 to find out if you are eligible.
Related Trial: Trimodal Lung-Sparing Treatment of Pleural Mesothelioma
Click here for an abstract of this trial - Phase II Study Using Chemotherapy Followed by Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced But Unresectable Malignant Pleural Mesothelioma
Click here for an abstract of this trial - Phase II Study of CBP501 + Pemetrexed + Cisplatin in Patients With Malignant Pleural Mesothelioma
Click here for an abstract of this trial - Phase II Study of Dasatinib in Patients With Previously Treated Malignant Mesothelioma
Click here for an abstract of this trial - Phase II Study of Pazopanib Hydrochloride in Patients With Malignant Pleural Mesothelioma
Click here for an abstract of this trial - Phase II Randomized Study of Pemetrexed Disodium Combined With Either Gemcitabine or Carboplatin in Patients With Advanced Malignant Mesothelioma of the Pleura
Click here for an abstract of this trial - Phase II Study of AZD2171 in Patients With Unresectable Malignant Pleural Mesothelioma
Click here for an abstract of this trial - Phase II Study of Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
Click here for an abstract of this trial - Phase II Study of Induction Combination Chemotherapy Comprising Methotrexate, Vinorelbine Ditartrate, and Cisplatin With or Without Surgery and Adjuvant Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma
Click here for an abstract of this trial - Phase II Study of PDX101 as Second-Line Therapy in Patients With Unresectable Malignant Pleural Mesothelioma
Click here for an abstract of this trial - Phase II Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma
Click here for an abstract of this trial - Phase I/II Study of Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma
Click here for an abstract of this trial - Phase I Study of Extrapleural Pneumonectomy, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma
Click here for an abstract of this trial - Phase I Dose-Escalation Study of Azacitidine In Combination With Temozolomide
Click here for an abstract of this trial - Phase I Study of SS1 (dsFv)-PE38 Immunotoxin in Combination With Pemetrexed Disodium and Cisplatin in Patients With Unresectable Maligant Epithelial Mesothelioma
Click here for an abstract of this trial - Phase I Study To Find the Best Dose of SU011248 When Given With Pemetrexed, Pemetrexed and Cisplatin Or Premetrexed and Carboplatin In Patients With Advanced Solid Tumors
Click here for an abstract of this trial - Phase I Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma
Click here for an abstract of this trial - Phase I Study of Erlotinib in Patients With Solid Tumors and Hepatic or Renal Dysfunction
Click here for an abstract of this trial - Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors
Click here for an abstract of this trial - Phase I Study of Anti-Mesothelin Monoclonal Antibody MORAB-009 in Patinets With Recurrent Advanced Mesothelin-Expressing Tumors
Click here for an abstract of this trial - Phase I Study Using Sunitinib Plus Radiation Therapy for Cancer Patients
Click here for an abstract of this trial - Phase I Study of Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis
Click here for an abstract of this trial - Phase I Study of Cisplatin, Imatinib Mesylate, and Pemetrexed in Malignant Mesothelioma Patients
Click here for an abstract of this trial - Phase I Study of Gene Induction Mediated by Sequential Decitabine/Desipeptide Infusion in Subjects With Pulmonary and Pleural Malignancies
Click here for an abstract of this trial - Phase I Study of Flavopiridol in Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies
Click here for an abstract of this trial - Phase I Study of Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors
Click here for an abstract of this trial - Phase I Study of Gene Therapy for Pleural Malignancies
Click here for an abstract of this trial - Phase I Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer
Click here for an abstract of this trial - Phase I Pilot Study of Wilms Tumor-1 Analog Peptide Vaccine and Sargramostim (GM-CSF) in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma
Click here for an abstract of this trial
- Diagnostic Trials
Study of the Use of Breathing Synchronized CT and PET Scans in Radiation Therapy Treatment Planning
Click here for an abstract of this trialMultiple Biomarkers in Undiagnosed Pleural Effusion
Click here for an abstract of this trialStudy of the Etanidazole Derivative EF5 for the Detection of Hypoxia and Vascularity in Patients With Intraperitoneal or Pleural Malignancies Treated With Photodynamic Therapy
Click here for an abstract of this trial
- Supportive Care Trials
Phase III Study of Fentanyl Sublingual Spray for Breakthrough Cancer Pain in Patients Who are Opiod Tolerant
Click here for an abstract of this trial
- Biomarker/Laboratory Analysis Trials
Study of Early Detection of Mesothelioma Biomarkers in Patients With Asbestos and Vermiculite Exposure
Click here for an abstract of this trialMultiple Biomarkers in Undiagnosed Pleural Effusion
Click here for an abstract of this trial
FURTHER INFORMATION - CLINICAL TRIALS
National Institutes of Health (NIH) Clinical Center, Bethesda, MD
The Informed Consent process for patients in clinical trials.
Investigational drugs are those under evaluation in the clinical trial system, but not yet approved by the Food and Drug Administration to be legally marketed and sold. More on investigational drugs.
The process of developing new mesothelioma drugs.
The Department of Veterans Affairs and the National Cancer Institute have an agreement to increase access of eligible veterans to all phases of NCI-sponsored prevention, diagnostic and treatment clinical trial. Click here for more information.
The Community Clinical Oncology Program (CCOP) is a nationwide network that ensures that cancer patients have access to medical care in their own communities.
Sources for information on this page:
National Institutes of Health, Understanding Clinical Trials
To receive a FREE Mesothelioma Web information packet** or to make a request, please fill out the following form :
Contact Us
News
- Mesothelioma News
- International News
- Pharmaceutical News
- Environmental News
- Medical Journal Articles
Resources
- Leading Cancer Links
- Financial Assistance, Compensation, and Legal Rights
- About Us
- Privacy Policy
- Disclaimer and Sponsorship Information
This site complies with the HONcode standard for trustworthy health information: verify here
If you would like to receive a FREE information packet or have questions about mesothelioma, call us at:
Toll-Free 1-877-367-6376

